What is the main business of Supplementation Institute?

The main business activity of Supplementation Institute focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on April 2, 2025.

Where is the headquarters located?

The headquarters is located at: ul. Józefa Ignacego Kraszewskiego 14, 82-200 Malbork.

Who is on the management board?

The management board includes Michał Maksymilian Cerapiński (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 20,000 (approx. $5,402).

What period do the latest financial data cover?

The latest available financial statement covers the period from April 2, 2025 to December 31, 2025.

How much revenue was generated?

In 2025, the company generated total revenue of $67,621.

Is the company profitable?

Yes, in 2025 the company achieved a net profit of $20,310.

Which cost dominates operating expenses?

The largest operating cost category falls under other operating costs. This category amounted to $33,258 in 2025, representing 77% of all operating expenses.

Supplementation Institutesp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2025-04-02

Share capital

20,000.00 PLN

Registered address

ul. Józefa Ignacego Kraszewskiego 14/14, 82-200 Malbork, Poland

Financials

Filing timeliness

The financial statement for 2025 was filed on time.

202515/07/2026

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 67.62kMedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD 20.31kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 43.18kMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 83.28kMedianUSD 883.09kAverageUSD 31.39m

Industry

Authorized Representatives

Daniel Adam Stolc – Management Board Member

Michał Maksymilian Cerapiński – President of the Management Board

Manner of representation

Each member of the management board independently.

Ownership

Owner	Shares	Share value	Stake
Michał Maksymilian Cerapińskiage 32	200	$2,701.24	50%
Daniel Adam Stolcage 33	200	$2,701.24	50%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2025-04-15.

Nest Bank
66 2530 0008 2049 1085 5940 0001

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Zakłady Farmaceutyczne PolpharmaS.A.	$780,704,907.94	polpharma.pl
Labofarmsp. z o.o.	$6,814,569.78	labofarm.pl
PoltregS.A.	$1,906,011.66	poltreg.com
Human BiomeS.A.	$888,361.19	human-biome.com
LideoS.A.	$95,067.91	lideo.tech
Munar PharmaS.A.	$85,649.72	munar.pl
BIO Animalisp. z o.o.	$49,176.96	proanimali.com
Ampliconsp. z o.o.	$48,330.99	amplicon.pl
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com

FAQ

Last updated: 2026-07-15